Molecular basis of antifolate resistance

Cancer and Metastasis Reviews

Volumn 26, Issue 1, 2007, Pages 153-181

  Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antifolates; Chemotherapy; Drug resistance; Folate pools; Folate dependent enzymes; Folates; Influx and efflux transporters

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; 2 DEAMINO 2 METHYL 10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; AG 2037; AMINOPTERIN; BCG 9331; CYTARABINE; CYTIDINE DERIVATIVE; DEXAMETHASONE; EDATREXATE; ENZYME INHIBITOR; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GEMCITABINE; GW 1843; HISTONE DEACETYLASE INHIBITOR; LOMETREXOL; METHOTREXATE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; NOLATREXED; OSI 7904; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PIRITREXIM; PLEVITREXED; PRALATREXATE; PROTEIN S ISOPRENYLCYSTEINE O METHYLTRANSFERASE; RALTITREXED; RETINOIC ACID; THYMIDYLATE SYNTHASE; TRIMETREXATE; TRIMETREXATE GLUCURONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG TRANSPORT; ENZYME INHIBITION; FOLATE METABOLISM; HISTIOCYTIC LYMPHOMA; HUMAN; IN VITRO SELECTION; IN VIVO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REMISSION; REVIEW; TUMOR CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; NEOPLASMS;

EID: 33947375647     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9049-z     Document Type: Review

References (250)

1. Stokstad, E. L. R. (1990). Folic acid metabolism in health and disease. In M. F. Picciano & E. L. R. Stokstad (Eds.). New York: Wiley-Liss, pp. 1-21.
2. Appling, D. R. (1991). Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB Journal, 5, 2645-2651.
3. Titus, S. A., & Moran, R. G. (2000). Retrovirally mediated complementation of the glyB phenotype. Cloning of a human gene encoding the carrier for entry of folates into mitochondria. Journal of Biological Chemistry, 275, 36811-36817.
4. Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, V. A. (1948). Temporary remissions in acute leukemia produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). New England Journal of Medicine, 238, 787-793.
5. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., et al. (1991). ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Research, 51, 5579-5586.
6. Cocconi, G., Cunningham, D., Van Custem, E., Francois, E., Gustavsson, B., Van Hazel, G., et al. (1998). Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Study Group. Journal of Clinical Oncology, 16, 2943-2952.
7. Shih, J., Chen, V. J., Gossett, L. S., Gates, S. B., McKellar, W. C., Habeck, L. L., et al. (1997). LY231514, a pyrrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Research, 57, 1116-1123.
8. Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., et al. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21, 2630-2636.
9. Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., Von Pawel, J., et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology, 22, 1589-1597.
10. Walling, J. (2006). From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Investigational New Drugs, 24, 37-77.
11. Assaraf, Y. G. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resistance Updates, 9, 227-246.
12. Domin, B. A., Cheng, Y. C., & Hakala, M. T. (1982). properties of a dihydrofolate reductase from a methotrexate-resistant subline of human KB cells and comparison with enzyme from KB parent cells and mouse S180 AT/3000 cells. Molecular Pharmacology, 21, 231-238.
13. Appleman, J. R., Prendergast, N., Delcamp, T. J., Freisheim, J. H., & Blakely, R. L. (1988). Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase. Journal of Biological Chemistry, 263, 10304-10313.
14. Rosowsky, A., Wright, J. E., Vadiya, C. M., & Forsch, R. A. (2000). The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent N (α)-(4-amino-4-deoxypteroyl)-N-(δ)- hemiphtaloyl-L-ornithine. Pharmacology & Therapeutics, 85, 191-205.
15. Goldman, I. D. (1974). The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts. Molecular Pharmacology, 10, 257-274.
16. Sirotnak, F. M., & Donsbach, R. C. (1974). The intracellular concentration dependence of antifolate inhibition of DNA synthesis in L1210 leukemia cells. Cancer Research, 34, 332-340.
17. White, J. C., Loftfield, S., & Goldman, I. D. (1975). The mechanism of action of methotrexate. III. Requirement of free intracellular methotrexate for maximal suppression of (14C) formate incorporation into nucleic acids and protein. Molecular Pharmacology, 11, 287-297.
18. Assaraf, Y. G., Ifergan, I., Kadry, W., & Pinter, R. Y. (2006). Computer modeling of antifolate inhibition of folate metabolism using hybrid functional petri nets. Journal of Theoretical Biology, 240, 637-647.
19. Jackson, R. C., & Harrap, K. R. (1973). Studies with a mathematical model of folate metabolism. Archives of Biochemistry and Biophysics, 158, 827-841.
20. Jackson, R. C., Niethammer, D., & Hart, L. I. (1977). Reactivation of dihydrofolate reductase inhibited by methotrexate or aminopterin. Archives of Biochemistry and Biophysics, 182, 646-656.
21. White, J. C. (1979). Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate. Studies with pure enzyme and computer modeling using network thermodynamics. Journal of Biological Chemistry, 254, 10889-10895.
22. White, J. C., & Goldman, I. D. (1981). Methotrexate resistance in a L1210 cell line resulting from increased dihydrofolate reductase, decreased thymidylate synthetase activity, and normal membrane transport. Computer simulations based on network thermodynamics. Journal of Biological Chemistry, 256, 5722-5727.
23. Moran, R. G., Werkheiser, W. C., & Zakrzewski, S. F. (1976). Folate metabolism in mammalian cells in culture. I. Partial characterization of the folate derivatives present in L1210 mouse leukemia cells. Journal of Biological Chemistry, 251, 3569-3575.
24. Sirotnak, F. M., DeGraw, J. I., Moccio, D. M., Samuels, L. L., & Goutas, L. J. (1984). New folate analogs of the 10-deazaaminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemotherapy and Pharmacology, 12, 18-25.
25. Schornagel, J. H., Verweij, J., de Mulder, P. H., Cognetti, F., Vermorken, J. B., Cappelaere, P., et al. (1995). Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. Journal of Clinical Oncology, 13, 1649-1655.
26. Pivot, X., Walder, S., Kelly, C., Ruxer, R., Totochaux, J., Stern, J., et al. (2001). Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Annals of Oncology, 12, 1595-1599.
27. Matin, K., Jacobs, S. A., Richards, T., Wong, M. K., Earle, M., Evans, T., et al. (2005). A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. American Journal of Clinical Oncology, 28, 439-444.
28. Huie, M., Carducci, M., Liu, G., Wilding, G., Marnocha, R., Izquierda, M., et al. (2005). Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. American Journal of Clinical Oncology, 28, 613-617.
29. Duch, D. S., Banks, S., Dev, I. K., Dickerson, S. H., Ferone, R., Heath, L. S., et al. (1993). Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Research, 53, 810-818.
30. Jackman, A. L., Kimbell, R., Aherne, G.W., Brunton, L., Jansen, G., Stephens, T. C., et al. (1997). Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clinical Cancer Research, 3, 911-921.
31. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M., et al. (1998). A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. Journal of Biological Chemistry, 273, 30189-30198.
32. Drori, S., Jansen, G., Mauritz, R., Peters, G. J., & Assaraf, Y. G. (2000). Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. Journal of Biological Chemistry, 275, 30855-30863.
33. Rothem, L., Ifergan, I., Kaufman, Y., Priest, D. G., Jansen, G., & Assaraf, Y. G. (2002). Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cells. Biochemical Journal, 367, 741-750.
34. Liani, L., Rothem, L., Bunni, M. A., Smith, C. A., Jansen, G., & Assaraf, Y. G. (2003). Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. International Journal of Cancer, 103, 587-599.
35. Gibbs, D. D., Theti, D. S., Wood, N., Green, M., Raynaud, F., Valenti, M., et al. (2005). BGC945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors. Cancer Research, 65, 11721-11728.
36. Beardsley, G. P., Moroson, B. A., Taylor, E. C., & Moran, R. G. (1989). A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. Journal of Biological Chemistry, 264, 21047-21051.
37. Zhang, Y., Desharnais, J., Marsilje, T. H., Li, C., Hedrick, M. P., Gooljarsingh, L. T., et al. (2003). Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR TFase: 10-(trifluoroacetyl) -5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid. Biochemistry, 42, 6043-6056.
38. McGuire, J. J., Russell, C. A., & Balinska, M. (2000). Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophoretically distinct. Journal of Biological Chemistry, 275, 13012-13016.
39. Baugh, C. M., Krumdieck, C. L., & Nair, M. G. (1973). Poly-γ-glutamyl metabolites of methotrexate. Biochemical and Biophysical Research Communications, 52, 27-34.
40. McBurney, M. W., & Whitmore, G. F. (1974). Isolation and biochemical characterization of folate deficient mutants of Chinese hamster ovary cells. Cell, 2, 173-182.
41. Moran, R. G. (1999). Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: An overview. Seminars in Oncology, 26, 24-32.
42. Schirch, V., & Strong, W. B. (1989). Interaction of folylpolyglutamates with enzymes in one-carbon metabolism. Archives of Biochemistry and Biophysics, 269, 371-380.
43. Allegra, C. J., Chabner, B. A., Drake, J. C., Lutz, R., Rodbard, D., & Jolivet, J. (1985). Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. Journal of Biological Chemistry, 260, 9720-9726.
44. Allegra, C. J., Hoang, K., Yeh, G. C., Drake, J. C., & Baram, J. (1987). Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. Journal of Biological Chemistry, 262, 13520-13526.
45. Baggott, J. E., Vaughn, W. H., & Hudson, B. B. (1986). Inhibition of 5-aminoimidazole-4-carboxamide-ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide-riboside and ribotide. Biochemical Journal, 236, 193-200.
46. Matherly, L. H., & Goldman, I. D. (2003). Membrane transport of folates. Vitamins and Hormones, 66, 403-456.
47. Zeng, H., Chen, Z. S., Belinsky, M. G., Rea, P. A., & Kruh, G. D. (2001). Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Research, 61, 7225-7232.
48. Wielinga, P., Hooijberg, J. H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer, N., et al. (2005). The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Research, 65, 4425-4430.
49. Volk, E. L., & Schneider, E. (2003). Wild type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Research, 63, 5538-5543.
50. Jackson, R. C., Fry, D. W., Boritzki, T. J., Besserer, J. A., Leopold, W. R., Sloan, B. J., et al. (1984). Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Advances in Enzyme Regulation, 22, 187-206.
51. Webber, S., Bartlett, C. A., Boritzki, T. J., Hillard, J. A., Howland, E. F., Johnston, A. L., et al. (1996). AG337, a novel lipophilic thymidylate synthase inhibitor: In vivo preclinical studies. Cancer Chemotherapy and Pharmacology, 37, 509-517.
52. Lin, B. F., Huang, R. F., & Shane, B. (1993). Regulation of folate and one-carbon metabolism in mammalian cells. III. Role of mitochondrial folylpoly-γ-glutamate synthetase. Journal of Biological Chemistry, 268, 21674-21679.
53. Zhao, I. D., & Goldman, I. D. (2003). Resistance to antifolates. Oncogene, 22, 7431-7457.
54. Ferguson, P. L., & Flintoff, W. F. (1999). Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. Journal of Biological Chemistry, 274, 16269-16279.
55. Liu, X. Y., & Matherly, L. H. (2002). Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochimica et Biophysica Acta, 1564, 333-342.
56. Saier, M. H., Beatty, J. T., Goffeau, A., Harley, K. T., Heijne, W. H., Huang, S. C., et al. (1999). The major facilitator superfamily. Journal of Molecular Microbiology and Biotechnology, 1, 257-279.
57. Yang, C.-H., Sirotnak, F. M., & Dembo, M. (1984). Interactions between anions and the reduced folate/methotrexate transport system in L1210 cell plasma membrane vesicles: Directional symmetry and anion specificity for differential mobility of loaded and unloaded carrier. Journal of Membrane Biology, 79, 285-292.
58. Zhao, R., Gao, F., Wang, Y., Diaz, G. A., Gelb, B. D., & Goldman, I. D. (2001). Impact of the reduced folate carrier on the accumulation of active thiamine metabolites in murine leukemia cells. Journal of Biological Chemistry, 276, 1114-1118.
59. Zhao, R., Gao, F., & Goldman, I. D. (2002). Reduced folate carrier transports thiamine monophosphate: An alternative route for thiamine delivery into mammalian cells. American Journal of Physiology. Cell Physiology, 282, C1512-C1517.
60. Goldman, I. D. (1971). The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Annals of the New York Academy of Sciences, 186, 400-422.
61. Sierra, E. E., Brigle, K. E., Spinella, M. J., & Goldman, I. D. (1997). pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH. Biochemical Pharmacology, 53, 223-231.
62. Sierra, E. E., & Goldman, I. D. (1998). Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochemical Pharmacology, 55, 1505-1512.
63. Assaraf, Y. G., Babani, S., & Goldman, I. D. (1998). Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in Chinese hamster ovary cells. Journal of Biological Chemistry, 273, 8106-8111.
64. Elnakat, H., & Ratnam, M. (2004). Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Advanced Drug Delivery Reviews, 56, 1067-1084.
65. Elnakat, H., & Ratnam, M. (2006). Role of folate receptor genes in reproduction and related cancers. Frontiers in Bioscience, 11, 506-519.
66. Shen, F., Wu, M., Ross, J. F., Miller, D., & Ratnam, M. (1995). Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: Protein characterization and cell type specificity. Biochemistry, 34, 5660-5665.
67. Wang, X., Shen, F., Freisheim, J. H., Gentry, L. E., & Ratnam, M. (1992). Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochemical Pharmacology, 44, 1898-1901.
68. Ross, J. F., Wang, H., Behm, F. G., Mathew, P., Wu, M., Booth, R., et al. (1999). Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer, 85, 348-357.
69. Shen, F., Ross, J. F., Wang, X., & Ratnam, M. (1994). Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA expression, immunoreactivity, and tissue specificity. Biochemistry, 33, 1209-1215.
70. Borst, P., & Oude Elferink, R. O. (2002). Mammalian ABC transporters in health and disease. Annual Review of Biochemistry, 71, 537-592.
71. Deeley, R. G., Westlake, C., & Cole, S. P. (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiological Reviews, 86, 849-899.
72. Loo, T. W., & Clarke, D. M. (1994). Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry, 33, 14049-14057.
73. Hafkemeyer, P., Dey, S., Ambudkar, S. V., Hrycyna, C. A., Pastan, I., & Gottesman, M. M. (1998). Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry, 37, 16400-16409.
74. Cole, S. P., Bhardwaj, G., Gerlach, J., Mackie, J. E., Grant, C., Almquist, K. C., et al. (1992). Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science, 258, 1650-1654.
75. Cools, J., Maertens, C., & Marynen, P. (2005). Resistance to tyrosine kinase inhibitors: Calling on extra forces. Drug Resistance Updates, 8, 119-129.
76. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5, 219-234.
77. Hakala, M. T. (1965). On the nature of permeability of sarcoma-180 cells to amethopterin in vitro. Biochimica et Biophysica Acta, 102, 210-225.
78. Goldman, I. D. (1969). Transport energetics of the folic acid analogue, methotrexate, in L1210 leukemia cells. Enhanced accumulation by metabolic inhibitors. Journal of Biological Chemistry, 244, 3779-3785.
79. Dembo, M., Sirotnak, F. M., & Moccio, D. M. (1984). Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: Further evidence for separate influx and efflux systems with different energetic requirements. Journal of Membrane Biology, 78, 9-17.
80. Henderson, G. B., & Zevely, E. M. (1984). Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. Journal of Biological Chemistry, 259, 1526-1531.
81. Henderson, G. B., Tsuji, J. M., & Kumar, H. P. (1986). Characterization of the individual transport routes that mediate the influx and efflux of methotrexate in CCRF-CEM human lymphoblastic cells. Cancer Research, 46, 1633-1638.
82. Saxena, M., & Henderson, G. B. (1996). MOAT4, a novel multispecific organic-anion transporter for glucuronides and mercapturates in mouse L1210 cells and human erythrocytes. Biochemical Journal, 320, 273-281.
83. Saxena, M., & Henderson, G. B. (1996). Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells. Biochemical Pharmacology, 51, 974-982.
84. Sirotnak, F. M., & O'Leary, D. (1991). The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis- and trans-effects of inhibitors. Cancer Research, 51, 1412-1417.
85. Masuda, H., I'izuka, M., Yamazaki, Y., Nishigaki, M., Kato, R., Ni'inuma, Y., et al. (1997). Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Research, 57, 3506-3510.
86. Heijn, M., Hooijberg, J. H., Scheffer, G. L., Szabo, G., Westerhoff, H. V., & Lankelma, J. (1997). Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochimica et Biophysica Acta, 1326, 12-22.
87. Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J., Noordhuis, P., et al. (1999). Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Research, 59, 2532-2535.
88. Kool, M., van der Linden, M., De Haas, M., Scheffer, G. L., De Vree, J. M. L., Smith, A. J., et al. (1999). MRP3, an organic anion transporter able to transport anti-cancer drugs. In Proceedings of the National Academy of Sciences of the United States of America, 96, 6914-6919.
89. Ito, K., Oleschuk, C. J., Westlake, C., Vasa, M. Z., Deeley, R. G., Cole, S. P. (2001). Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of membrane transport activity. Journal of Biological Chemistry, 276, 38108-38114.
90. Ito, K., Olsen, S. L., Qiu, W., Deeley, R. G., & Cole, S. P. (2001). Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. Journal of Biological Chemistry, 276, 15616-15624.
91. Sczesny, F., Hempel, G., Boos, G., & Blaschke, G. (1998). Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites. Journal of Chromatography. B, Biomedical Sciences and Applications, 718, 177-185.
92. Assaraf, Y. G., & Goldman, I. D. (1997). Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. Journal of Biological Chemistry, 272, 17460-17466.
93. Kusuhara, H., Han, Y.-H., Shimoda, M., Kokue, E., Suzuki, H., & Sugiyama, Y. (1998). Reduced folate derivatives are endogenous substrates for cMOAT in rats. American Journal of Physiology, 275, G789-G796.
94. Sirotnak, F. M., Kurita, S., & Hutchison, D. J. (1968). On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia. Cancer Research, 28, 75-80.
95. Niethammer, D., & Jackson, R. C. (1975). Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. European Journal of Cancer, 11, 845-854.
96. Hill, B. T., Bailey, B. D., White, J. C., & Goldman, I. D. (1979). Characteristics of transport of 4-amino antifolates and folate compounds by two cell lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Research, 39, 2440-2446.
97. Sirotnak, F. M., Moccio, D. M., Kelleher, L. E., & Goutas, L. J. (1981). Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Research, 41, 4447-4452.
98. Assaraf, Y. G., & Schimke, R. T. (1987). Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry. In Proceedings of the National Academy of Sciences of the United States of America, 84, 7154-7158.
99. Moscow, J. A., Gong, M. K., He, R., Sgagias, M. K., Dixon, K. H., Anzick, A. L., et al. (1995). Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Research, 55, 3790-3794.
100. Moscow, J. A., Connoly, T., Myers, T. G., Cheng, C. C., Paull, K., & Cowan, K. H. (1997). Reduced folate carrier gene (RFC1) expression and antifolate-resistance in transfected and non-selected cell lines. International Journal of Cancer, 72, 184-190.
101. Kobayashi, H., Takemura, Y., & Ohnuma, T. (1998). Variable expression of RFC1 in human leukemia cell lines resistant to antifolates. Cancer Letters, 124, 135-142.
102. Ma, D., Huang, H., & Moscow, J. A. (2000). Down-regulation of the reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells. Biochemical and Biophysical Research Communications, 279, 891-897.
103. Worm, J., Kirkin, A. F., Dzhandzhugazyan, K. N., & Guldberg, P. (2001). Methylation-dependent silencing of the folate carrier gene in inherently methotrexate-resistant human breast cancer cells. Journal of Biological Chemistry, 276, 39990-40000.
104. Ding, B. C., Whetstine, J. R., Witt, T. L., Schuetz, J. D., & Matherly, L. H. (2001). Repression of the human reduced folate carrier gene expression by wild type p53. Journal of Biological Chemistry, 276, 8713-8719.
105. Rothem, L., Aronheim, A., & Assaraf, Y. G. (2003). Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. Journal of Biological Chemistry, 278, 8935-8941.
106. Rothem, L., Stark, M., Kaufman, Y., Mayo, L., & Assaraf, Y. G. (2004). Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. Journal of Biological Chemistry, 279, 374-384.
107. Rothem, L., Stark, M., & Assaraf, Y. G. (2004). Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene. Molecular Pharmacology, 66, 1536-1543.
108. Wettergren, Y., Odin, E., Nilsson, S., Willen, R., Carlsson, G., & Gustavson, B. (2005). Low expression of reduced folate carrier-1 and folylpolyglutamate synthetase correlates with lack of a deleted in colorectal carcinoma mRNA splice variant in normal-appearing mucosa of colorectal carcinoma patients. Cancer Detection and Prevention, 29, 348-355.
109. Stark, M., & Assaraf, Y. G. (2006). Loss of Sp1 function via inhibitory phosphorylation in antifolate-resistant human leukemia cells with down-regulation of the reduced folate carrier. Blood, 107, 708-715.
110. Kaufman, Y., Ifergan, I., Rothem, L., Jansen, G., & Assaraf, Y. G. (2006). Coexistence of multiple mechanisms of PT523-resistance in human leukemia cells harboring three reduced folate carrier alleles: Transcriptional silencing, inactivating mutations and allele loss. Blood, 107, 3288-3294.
111. Gorlick, R., Goker, E., Trippett, T., Steinherz, P., Elisseyef, Y., Mazumdar, M., et al. (1997). Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood, 89, 1013-1018.
112. Zhang, L., Taub, J. W., Williamson, M., Wong, S. C., Hukku, B., Pullen, J., et al. (1998). Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clinical Cancer Research, 4, 2169-2177.
113. Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., et al. (1999). Mechanism of methotrexate resistance in osteosarcoma. Clinical Cancer Research, 5, 621-627.
114. Belkov, V. M., Krynetski, E. Y., Schuetz, J. D., Yanishevski, Y., Masson, E., Mathew, S., et al. (1999). Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood, 93, 1643-1650.
115. Rots, M. G., Willey, J. C., Jansen, G., Van Zantwijk, C. H., Noordhuis, P., DeMuth, J. P., et al. (2000). mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia, 14, 2166-2175.
116. Ifergan, I., Meller, I., Issakov, J., & Assaraf, Y. G. (2003). Reduced folate carrier protein expression in osteosarcoma: Implications for the prediction of tumor chemosensitivity. Cancer, 98, 1958-1966.
117. Levy, A. S., Sather, H. N., Steinherz, P. G., Sowers, R., La, M., Moscow, J. A., et al. (2003). Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: A Children's Cancer Group Study. Journal of Pediatric Hematology/Oncology, 25, 688-695.
118. Ferreri, A. J., Dell'Oro, S., Capello, D., Ponzoni, M., Luzzolino, P., Rossi, D., et al. (2004). Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. British Journal of Haematology, 126, 657-664.
119. Wong, S. C., Proefke, S. A., Bhushan, A., & Matherly, L. H. (1995). Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. Journal of Biological Chemistry, 270, 17468-17475.
120. Prasad, P. D., Ramamoorthy, S., Leibach, F. H., & Ganapathy, V. (1995). Molecular cloning of the human placental folate transporter. Biochemical and Biophysical Research Communications, 206, 681-687.
121. Dixon, K. H., Lanpher, B. C., Chiu, J., Kelley, K., & Cowan, K. H. (1995). A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. Journal of Biological Chemistry, 269, 17-20.
122. Williams, F. M. R., Murray, R. C., Underhill, T. M., & Flintoff, W. F. (1994). Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. Journal of Biological Chemistry, 269, 5810-5816.
123. Brigle, K. E., Spinella, M. J., Sierra, E. E., & Goldman, I. D. (1995). Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. Journal of Biological Chemistry, 270, 22974-22979.
124. Zhao, R., Sharina, I. G., & Goldman, I. D. (1999). Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Molecular Pharmacology, 56, 68-76.
125. Roy, K., Tolner, B., Chiao, J. H., & Sirotnak, F. M. (1998). A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. Journal of Biological Chemistry, 273, 2526-2531.
126. Mauritz, R., Peters, G. J., Priest, D. G., Assaraf, Y. G., Drori, S., Kathmann, I., et al. (2002). Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochemical Pharmacology, 63, 105-115.
127. Zhao, R., Assaraf, Y. G., & Goldman, I. D. (1998). A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate and an obligatory anion requirement for transport function. Journal of Biological Chemistry, 273, 19065-19071.
128. Zhao, R., Assaraf, Y. G., & Goldman, I. (1998). A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. Journal of Biological Chemistry, 273, 7873-7879.
129. Zhao, R., Hanscom, M., Chattopadhyay, S., & Goldman, I. D. (2004). Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: Association with the presence of a secondary transport pathway. Cancer Research, 64, 3313-3319.
130. Whetstine, J. R., Gifford, A. J., Witt, T., Liu, X. Y., Flately, R. M., Norris, M., et al. (2001). Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency G/A variant at position 80 and transport properties of the His (27) and Arg(27) carriers. Clinical Cancer Research, 7, 3416-3422.
131. Gifford, A. J., Haber, M., Witt, T. L., Whetstine, J. R., Taub, J.W., Matherly, L. H., et al. (2002). Role of the E45K reduced folate carrier mutation in methotrexate resistance in human leukemia cells. Leukemia, 16, 2379-2387.
132. Kaufman, Y., Drori, S., Cole, P. D., Kamen, B. A., Sirota, J., Ifergan, I., et al. (2004). Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer, 100, 773-782.
133. Yang, R., Sowers, R., Mazza, B., Healey, J. H., Huvos, A., Grier, H., et al. (2003). Sequence alterations in the reduced folate carrier are observed in
134. Flintoff, W. F., Sadlish, H., Gorlick, R., Yang, R.,& Williams, F. M. (2004). Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcoma. Biochimica et Biophysica Acta, 1690, 110-117.
135. Whetstine, J. R., & Matherly, L. H. (2001). The basal promoters for the human reduced folate carrier gene are regulated by a GCbox and a cAMP-response element/AP-1-like element. Basis for tissue-specific gene expression. Journal of Biological Chemistry, 276, 6350-6358.
136. Whetstine, J. R., Witt, T. L., & Matherly, L. H. (2002). The human reduced folate carrier gene is regulated by the AP2 and Sp1 transcription factor families and a functional 61-base pair polymorphism. Journal of Biological Chemistry, 277, 43873-43880.
137. Liu, M., Whetsine, J. R., Payton, S. G., Ge, Y., Flatley, R. M., & Matherly, L. H. (2004). Roles of USF, Ikaros and Sp1 proteins in the transcriptional regulation of the human reduced folate carrier B promoter. Biochemical Journal, 383, 249-257.
138. Payton, S. G., Whetstine, J. R., Ge, Y., & Matherly, L. H. (2005). Transcriptional regulation of the human reduced folate carrier promoter C: Synergistic transactivation by Sp1 and C/EBP beta and identification of a downstream repressor. Biochimica et Biophysica Acta, 1727, 45-57.
139. Payton, S. G., Liu, M., Ge, Y., & Matherly, L. H. (2005). Transcriptional regulation of the human reduced folate carrier A1/A2 promoter: Identification of critical roles for the USF and GATA families of transcription factors. Biochimica et Biophysica Acta, 1731, 115-124.
140. Liu, M., Ge, Y., Payton, S. G., Aboukameel, A., Buck, S., Flately, R. M., et al. (2006). Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells. Clinical Cancer Research, 12, 608-616.
141. Ding, B. C., Witt, T. L., Hukku, B., Heng, H., Zhang, L., & Matherly, L. H. (2001). Association of deletions and translocations of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells. Biochemical Pharmacology, 61, 665-675.
142. Yang-Feng, T. L., Ma, Y.Y., Liang, R., Prasad, P. D., Leibach, F. H., & Ganapathy, V. (1995). Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization. Biochemical and Biophysical Research Communications, 210, 874-879.
143. Whitehead, V. M., Vuhich, M. J., Lauer, S. J., Mahoney, D., Carroll, A. J., Shuster, J. J., et al. (1992). Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) Blineage acute lymphoblastic leukemia: A pediatric oncology group study. Blood, 80, 1316-1323.
144. Wong, S. C., Zhang, L., Proefke, S. A., Hukku, B., & Matherly, L. H. (1998). Gene amplification and increased expression of the reduced folate carrier in transport elevated K562 cells. Biochemical Pharmacology, 55, 1135-1138.
145. Drori, S., Sprecher, H., Shemer, G., Jansen, G., Goldman, I. D., & Assaraf, Y. G. (2000). Characterization of a human alternatively spliced truncated reduced folate carrier (RFC) increasing folate accumulation in parental leukemia cells. European Journal of Biochemistry, 267, 690-702.
146. Alt, F. W., Kellems, R. E., & Schimke, R. T. (1978). Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. Journal of Biological Chemistry, 253, 1357-1370.
147. Nunberg, J. H., Kaufman, R. J., Schimke, R. T., Urlaub, G., & Chasin, L. A. (1978). Amplified dihydrofolate reductase genes are localized to a homogenously staining region of a single chromosome in a methotrexate-resistant Chinese hamster ovary cell line. In Proceedings of the National Academy of Sciences of the United States of America, 75, 5553-5556.
148. Dolnick, B. J., Berenson, R. J., Bertino, J. R., Kaufman, R. J., Nunberg, J. H., & Schimke, R. T. (1979). Correlation of dihydrofolate reductase elevation with gene amplification in a homogenously staining chromosomal region in L5178Y cells. Journal of Cell Biology, 83, 394-402.
149. Mini, E., Srimatkandada, S., Medina, W. D., Moroson, B. A., Carman, M. D., & Bertino, J. R. (1985). Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemia CCRF-CEM cells. Cancer Research, 45, 317-324.
150. Kaufman, R. J., Brown, P. C., & Schimke, R. T. (1979). Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. In Proceedings of the National Academy of Sciences of the United States of America, 76, 5669-5673.
151. Hamkalo, B. A., Farnham, P. J., Johnston, R., & Schimke, R. T. (1985). Ultrastructural features of minute chromosomes in a methotrexate- resistant mouse 3T3 cell line. In Proceedings of the National Academy of Sciences of the United States of America, 82, 1126-1130.
152. Horns, R. C., Dower, W. J., & Schimke, R. T. (1984). Gene amplification in a leukemic patient treated with methotrexate. Journal of Clinical Oncology, 2, 2-7.
153. Trent, J. M., Buick, R. N., Olson, S., Horns, R. C. Jr, & Schimke, R. T. (1984). Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. Journal of Clinical Oncology, 2, 8-15.
154. Knuutila, S., Bjorkvist, A. M., Autio, K., Tarkannen, M., Wolf, M., Monni, O., et al. (1998). DNA copy number amplifications in human neoplasms: Review of comparative genomic hybridization studies. American Journal of Pathology, 152, 1107-1123.
155. Chu, E., Takimoto, C. H., Voeller, D., Grem, J. L., & Allegra, C. J. (1993). Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry, 32, 4756-4760.
156. Tai, N., Schmitz, J. C., Chen, T. M., & Chu, E. (2004). Characterization of cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA. Biochemical Journal, 378, 999-1006.
157. Bystroff, C., & Kraut, J. (1991). Crystal structure of the unliganded Escherichia coli dihydrofolate reductase. Ligand-induced conformational changes and cooperativity in binding. Biochemistry, 30, 2227-2239.
158. Skacel, N., Menon, L. G., Mishra, P. J., Peters, R., Banerjee, D., Bertino, J. R., et al. (2005). Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment. Journal of Biological Chemistry, 280, 22721-22731.
159. Albrecht, A. M., Biedler, J. L., & Hutchinson, D. J. (1972). Two different species of dihydrofolate reductase in mammalian cells differentially resistant to amethopterin and methasquin. Cancer Research, 32, 1539-1546.
160. Jackson, R. C., Hart, L. I., & Harrap, K. R. (1976). Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrofolate reductases. Cancer Research, 36, 1991-1997.
161. Flintoff, W. F., & Essani, K. (1976). Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry, 19, 4321-4327.
162. Goldie, J. H., Krystal, G., Guauskas, G., & Dedhar, S. (1980). A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells. European Journal of Cancer, 16, 1539-1546.
163. Haber, D. A., Beveeley, S. M., Kiely, M. L., & Schimke, R. T. (1981). Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. Journal of Biological Chemistry, 256, 9501-9510.
164. Simonsen, C. C., & Levinson, A. D. (1983). Isolation and expression of an altered mouse dihydrofolate reductase cDNA. In Proceedings of the National Academy of Sciences of the United States of America, 80, 2495-2499.
165. Melera, P. W., Davide, J. P., Hession, C. A., & Scotto, K. W. (1984). Phenotypic expression in Escherichia coli and nucleotide sequence of two Chinese hamster lung cell cDNAs encoding different dihydrofolate reductases. Molecular and Cellular Biology, 4, 38-48.
166. Melera, P. W., Davide, J. P., & Oen, H. (1988). Antifolate-resistant Chinese hamster cells. Molecular basis for the biochemical and structural heterogeneity among dihydrofolate reductases produced by drug-sensitive and drug-resistant cell lines. Journal of Biological Chemistry, 263, 1978-1988.
167. Miyachi, H., Takemura, Y., Kobayashi, H., & Ando, Y. (1995). Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate. Cancer Letters, 88, 93-99.
168. Srimatkandada, S., Scheitzer, B. I., Moroson, B. A., Dube, S., & Bertino, J. R. (1989). Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. Journal of Biological Chemistry, 264, 3524-3528.
169. McIvor, R. S., & Simonsen, C. C. (1990). Isolation and characterization of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L5178Y cells. Nucleic Acids Research, 18, 7025-7032.
170. Dicker, A. P., Volkenandt, M., Schweiter, B. I., Banerjee, D., & Bertino, J. R. (1990). Identification and characterization of a mutation in the dihydrofolate reductase gene from the methotrexate-resistant Chinese hamster ovary cell line Pro-3 MtxRIII. Journal of Biological Chemistry, 265, 8317-8321.
171. Spencer, H. T., Sorrentino, B. P., Pui, C. H., Chunduru, S. K., Sleep, S. E., & Blakely, R. L. (1996). Mutations in the gene for human dihydrofolate reductase: An unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia, 10, 439-446.
172. Heidelberger, C., Chaudhuri, N. K., Dannenberg, P., Mooren, D., Griesbach, L., Duschinsky, R., et al. (1957). Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature, 179, 663-666.
173. O'Connor, B. M., Jackman, A. L., Crossley, P. H., Freemantle, S. E., Lunec, J., & Calvert, A. H. (1992). Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: A novel folate-based thymidylate synthase inhibitor. Cancer Research, 52, 1137-1143.
174. Freemantle, S. E., Jackman, A. L., Kelland, L. R., Calvert, A. H., & Lunec, J. (1995). Molecular characterization of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. British Journal of Cancer, 71, 925-930.
175. Jackman, A. L., Ferrugia, D. C., Gibson, W., Kimbell, R., Harrap, K. R., Stephens, T. C., et al. (1995). ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. European Journal of Cancer, 31A, 1277-1282.
176. Drake, J. C., Allegra, C. J., Moran, R. G., & Johnston, P. G. (1996). Resistance to tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell lines. Biochemical Pharmacology, 51, 1349-1355
177. Tong, Y., Liu-Chen, X., Ercikan-Abali, E. A., Zhao, S. C., Banerjee, D., Maley, F., et al. (1998). Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, thymitaq, and BW1843U89. Journal of Biological Chemistry, 273, 31209-31214.
178. Kitchens, M. E., Firsthoefel, A. M., Barbour, K.W., Spencer, H. T., & Berger, F. G. (1999). Mechanisms of acquired resistance to thymidylate synthase inhibitors: The role of enzyme stability. Molecular Pharmacology, 56, 1063-1070.
179. Wang, W., Marsh, S., Cassidy, J., & McLeod, H. L. (2001). Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Research, 61, 5505-5510.
180. Sigmond, J., Backus, H. H., Wouters, D., Temmink, O. H., Jansen, G., & Peters, G. J. (2003). Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDR human colon cancer cells is associated with thymidylate synthase overexpression. Biochemical Pharmacology, 66, 431-438.
181. Chu, E., Koeller, D. M., Casey, J. L., Drake, J. C., Chabner, B. A., Elwood, P. C., et al. (1991). Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. In Proceedings of the National Academy of Sciences of the United States of America, 88, 8977-8981.
182. Chu, E., Voeller, D. M., Jones, K. L., Takechi, T., Maley, G. F., Maley, F., et al. (1994). Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. Molecular and Cellular Biology, 14, 207-213.
183. Chu, E., & Allegra, C. J. (1996). The role of thymidylate synthase messenger RNA as an RNA binding protein. Bioessays, 18, 191-198.
184. Wang, T. L., Diaz, L. A., Romans, K., Bardelli, A., Saha, S., Galizia, G., et al. (2004). Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluouracil in metastatic colorectal cancer patients. In Proceedings of the National Academy of Sciences of the United States of America, 101, 3089-3094.
185. Tong, Y., Liu-Chen, X., Ercickan-Abali, E. A., Capiaux, G. M., Zhao, S. C., Banerjee, D., et al. (1998). Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethanemethylsulfonate-exposed human sarcoma HT1080 cells. Journal of Biological Chemistry, 273, 1161-11618.
186. Davis, S. T., & Berger, S. H. (1993). Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2′-deoxyuridine. Molecular Pharmacology, 43, 702-708.
187. Barbour, K. W., Berger, S. H., & Berger, F. G. (1990). Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Molecular Pharmacology, 37, 515-518.
188. Cowan, K. H., & Jolivet, J. (1984). A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. Journal of Biological Chemistry, 259, 10793-10800.
189. Sharif, K. A., Moscow, J. A., & Goldman, I. D. (1998). Concentrating capacity of the human reduced folate carrier (hRFC1) in human ZR-75 breast cancer cell lines. Biochemical Pharmacology, 55, 1683-1689.
190. Pizzorno, G., Mini, E., Coronnello, M., McGuire, J. J., Moroson, B. A., Cashmore, A. R., et al. (1988). Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Research, 48, 2149-2155.
191. Pizzorno, G., Chang, Y. M., McGuire, J. J., & Bertino, J. R. (1989). Inherent resistance of human squamaous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Research, 49, 5275-5280.
192. McCloskey, D. E., McGuire, J. J., Russell, C. A., Rowan, B. G., Bertino, J. R., Pizzorno, G., et al. (1991). Decreased folylpolyglutamate synthetase activity as a mechanism of resistance in CCRF-CEM human leukemia sublines. Journal of Biological Chemistry, 266, 6181-6187.
193. Li, W.W., Lin, J.T., Schweitzer, B. I., Tong, W. P., Niedzwiecki, D., & Bertino, J. R. (1992). Intrinsic resistance to methotrexate in humansoft tissue sarcoma cell lines. Cancer Research, 52, 3908-3913.
194. Pizzorno, G., Moroson, B. A., Cashmore, A. R., Russello, O., Mayer, J. R., Galivan, J., et al. (1995). Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Research, 55, 566-573.
195. Lu, K., Yin, M. B., McGuire, J. J., Bonmassar, E.,&Rustum, Y. M. (1995). Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochemical Pharmacology, 50, 391-398.
196. McGuire, J. J., Haile, W. H., Russell, C. A., Galvin, J. M., & Shane, B. (1995). Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure. Oncology Research, 7, 535-543.
197. McGuire, J. J., & Russel, C. A. (1998). Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines. Oncology Research, 10, 193-200.
198. Roy, K., Egan, M. G., Sirlin, S., & Sirotnak, F. M. (1997). Posttranscriptional mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. Journal of Biological Chemistry, 272, 6903-6908.
199. Zhao, R., Titus, S., Gao, F., Moran, R. G., & Goldman, I. D. (2000). Molecular analysis of murine cell lines resistant to 5,10- dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. Journal of Biological Chemistry, 275, 26599-26606.
200. Sanghani, S. P., Sanghani, P. C., & Moran, R. G. (1999). Identification of three key active site residues in the C-terminal domain of human recombinant folylpoly-gamma-glutamate synthetase by site-directed mutagenesis. Journal of Biological Chemistry, 274, 27018-27027.
201. Sun, X., Bognar, A. L., Baker, E. N., & Smith, C. A. (1998). Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase. In Proceedings of the National Academy of Sciences of the United States of America, 95, 6647-6652.
202. Galivan, J. (2000). Glutamyl hydrolase. Pharmacological role in enzymatic characterization. Pharmacology & Therapeutics, 85, 207-215.
203. Schneider, E., & Ryan, T. J. (2006). Gamma-glutamyl hydrolase and drug resistance. Clinica Chimica Acta, 374, 25-32.
204. Li, W. W., Waltham, M., Tong, W., Schweitzer, B. I., & Bertino, J. R. (1993). Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: A novel mechanism of intrinsic resistance to methotrexate (MTX). Advances in Experimental Medicine and Biology, 338, 635-638.
205. Rhee, M. S., Wang, Y., Nair, M. G., & Galivan, J. (1993). Acquisition of resistance to antifolates caused by enhanced gamma glutamyl hydrolase activity. Cancer Research, 53, 2227-2230.
206. Yao, R., Rhee, M. S., & Galivan, J. (1995). Effects of gammaglutamyl hydrolase on folyl- and antifolylpolyglutamates in cultured H35 hepatoma cells. Molecular Pharmacology, 48, 505-511.
207. Cole, P. D., Kamen, B. A., Gorlick, R., Banerjee, D., Smith, A. K., Magill, E., et al. (2001). Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Research, 61, 4599-4604.
208. Baggott, J. E., Heimburger, D. C., Krumdieck, C. L., & Butterworth, C. E. (1987). Folate conjugase activity in the plasma and tumors of breast cancer patients. American Journal of Clinical Nutrition, 46, 295-301.
209. Longo, G. S. A., Gorlick, R., Tong, W. P., Lin, S., Steinherz, P., Bertino, J. R. (1997). γ-glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemia. Oncology Research, 9, 259-263.
210. Rots, M. G., Pieters, R., Peters, G. J., Noordhuis, P., van Zantwijk, C. H., Kaspers, G. J. L., et al. (1999). Role of folylypolyglutamate synthetase and folylypolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood, 93, 1677-1683.
211. Cheng, Q., Cheng, C., Crews, K. R., Riberio, R. C., Pui, C. H., Relling, M. V., et al. (2006). Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. American Journal of Human Genetics, 79, 264-274.
212. Chave, K. J., Ryan, T. J., Chmura, S. E., & Galivan, J. (2003). Identification of nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene, 319, 167-175.
213. Cheng, Q., Wu, B., Kager, L., Panetta, J. C., Zheng, J., Pui, C. H., et al. (2004). A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics, 14, 557-567.
214. Nimec, Z., & Galivan, J. (1983). Regulatory aspects of the glutamylation of methotrexate in cultured hepatoma cells. Archives of Biochemistry and Biophysics, 226, 671-680.
215. Johnson, T. B., Nair, M. G., & Galivan, J. (1988). Role of folylpolyglutamate synthetase in the regulation of methotrexate polyglutamate formation in H35 hepatoma cells. Cancer Research, 48, 2426-2431.
216. Jansen, G., Barr, H. M., Kathmann, I., Bunni, M. A., Priest, D. G., Noordhuis, P., et al. (1999). Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: Role of increased folylpolyglutamylation, expanded folate pools and intralysosomal drug sequestration. Molecular Pharmacology, 5, 761-769.
217. Van der Wilt, C. L., Backus, H. H., Smid, K., Comijn, L., Veerman, G., Wouters, D., et al. (2001). Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Research, 61, 3675-3681.
218. Tse, A., & Moran, R. G. (1998). Cellular folates prevent polyglutamylation of 5,10-dideazatetrahydrofolate. A novel mechanism of resistance to antimetabolites. Journal of Biological Chemistry, 273, 25953-25960.
219. Jansen, G., Westerhof, G. R., Jarmuszewski, M. J., Kathmann, I., Rijksen, G., & Schornagel, J. H. (1990). Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. Journal of Biological Chemistry, 265, 18272-18277.
220. Assaraf, Y. G., Rothem, L., Hooijberg, J. H., Stark, M., Ifergan, I., Kathmann, I., et al. (2003). Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. Journal of Biological Chemistry, 278, 6680-6686.
221. Assaraf, Y. G., & Slotky, J. I. (1993). Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine. Journal of Biological Chemistry, 268, 4556-4566.
222. Zhao, R., Gao, F., & Goldman, I. D. (2001). Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochemical Pharmacology, 61, 857-865.
223. Sarkadi, B., Homolya, L., Szakacs, G., & Varadi, A. (2006). Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiological Reviews, 84, 1179-1236.
224. Stark, M., Rothem, L., Jansen, G., Scheffer, G. L., Goldman, I. D., & Assaraf, Y. G. (2003). Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Molecular Pharmacology, 64, 220-227.
225. Jacobs, S. A., Stoller, R. G., Chabner, B. A., & Johns, D. G. (1976). 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. Journal of Clinical Investigation, 57, 534-538.
226. Breithhaupt, H., & Kuenzlen, E. (1982). Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treatment Reports, 66, 1733-1741.
227. Rask, C., Albertioni, F., Bentzen, S. M., Schroeder, H., & Peterson, H. (1998). Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia. Acta Oncológica, 37, 277-284.
228. Fabre, G., Matherly, L. H., Favre, R., Catalin, J., & Cano, J. P. (1983). In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells. Cancer Research, 43, 4648-4652.
229. Fabre, G., Fabre, I., Matherly, L. H., Cano, J. P., & Goldman, I. D. (1984). Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. Journal of Biological Chemistry, 259, 5066-5072.
230. McGuire, J. J., Hsieh, P., & Bertino, J. R. (1984). Enzymatic synthesis of polyglutamate derivatives of 7-hydroxymethotrexate. Biochemical Pharmacology, 33, 1355-1361.
231. Fotoohi, K., Jansen, G., Assaraf, Y. G., Rothem, L., Stark, M., Kathmann, I., et al. (2004). Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: Implications for efficacy of methotrexate therapy. Blood, 104, 4194-4201.
232. Breedveld, P., Pluim, D., Cipriani, G., Dahlhaus, F., van Eijndhoven, M. A., de Wolf, C. J., et al. (2007). The effect of low pH on BCRP (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan and resveratrol in in vitro drug transport models. Molecular Pharmacology, 71, 240-249.
233. Winter-Vann, A. M., Kamen, B. A., Bergo, M. O., Young, S. G., Melnyk, S., James, S. J., et al. (2003). Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate. In Proceedings of the National Academy of Sciences of the United States of America, 100, 6529-6534.
234. Refsum, H., Helland, S., & Ueland, P. M. (1989). Fasting plasma homocysteine as a sensitive parameter of antifolate effect: A study of psoriasis patients receiving low-dose methotrexate treatment. Clinical Pharmacology and Therapeutics, 45, 510-520.
235. Molloy, A. M., & Scott, J. M. (2001). Folates and prevention of disease. Public Health Nutrition, 4, 601-609.
236. Rosenquist, T. H., Rataska, S. A., & Selhub, J. (1996). Homocysteine induces congenital defects of the heart and neural tube: Effect of folic acid. In Proceedings of the National Academy of Sciences of the United States of America, 93, 15227-15232.
237. Yi, P., Melnyk, S., Pogribna, M., Pogribny, I. P., Hine, R. J., & James, S. J. (2000). Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocsyteine and lymphocyte DNA hypomethylation. Journal of Biological Chemistry, 275, 29318-29323.
238. Bergo, M. O., Leung, G. K., Ambroziak, P., Otto, J. C., Casey, P. J., & Young, S. G. (2000). Targeted inactivation of the isoprenylcysteine carboxyl methyltrasferase gene causes mislocalization of KRas in mammalian cells. Journal of Biological Chemistry, 275, 17605-17610.
239. Tran, T., Shatnawi, A., Zheng, X., Kelley, K. M., & Ratnam, M. (2005). Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: A promising means to improved tumor detection and targeting. Cancer Research, 65, 4431-4441.
240. Qi, H., & Ratnam, M. (2006). Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Research, 66, 5875-5882.
241. Sirotnak, F. M., DeGraw, J. I., Chello, P. L., Moccio, D. M., & Dorick, D. M. (1982). Biochemical and pharmacological properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treatment Reports, 66, 351-358.
242. Wang, E. S., O'Connor, O., She, Y., Zelenetz, A. D., Sirotnak, F. M., & Moore, M. A. (2003). Activity of a novel anti-folate (PDX, 10-propargyl 10-deaza-aminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leukemia & Lymphoma, 44, 1027-1035.
243. Toner, L. E., Vrhohac, R., Smith, E. A., Gardner, J., Heaney, M., Gonen, M., et al. (2006). The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-hodgkin's lymphoma. Clinical Cancer Research, 12, 9240932.
244. O'Connor, O. A. (2006). Pralatrexate: An emerging new agent with activity in T-cell lymphomas. Current Opinion in Oncology, 18, 591-597.
245. O'Connor, O. A., & Hamlin, P. (2006). New drugs for the treatment of advanced-stage diffuse large cell lymphomas. Seminars in Hematology, 43, 251-256.
246. Sweet, D. L., Golomb, H. M., Ultmann, J. E., Miller, J. B., Stain, R. S., Lester, E. P., et al. (1980). Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Annals of Internal Medicine, 92, 785-790.
247. Qiu, A., Jansen, M., Sakaris, A., Min, S. H., Chattopadhyay, S., Tsai, E., et al. (2006). Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell, 127, 917-928.
248. Geller, J., Kronn, D., Jayabose, S., & Sandoval, C. (2002). Hereditary folate malabsorption: Family report and review of the literature. Medicine (Baltimore), 81, 51-68.
249. Wike-Hooley, J. L., Haveman, J., & Reinhold, H. S. (1984). The relevance of tumour pH to the treatment of malignant disease. Radiotherapy and Oncology, 2, 343-366.
250. 2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nature Medicine, 3, 117-182.